Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Up 79.6% in July

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 117,659 shares, an increase of 79.6% from the June 30th total of 65,513 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 659,333 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

Several brokerages recently issued reports on CLPBY. The Goldman Sachs Group lowered Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Coloplast A/S Trading Down 0.9%

Shares of CLPBY stock opened at $6.70 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.09 and a current ratio of 1.75. The company has a market capitalization of $15.10 billion, a price-to-earnings ratio of 47.86, a PEG ratio of 2.14 and a beta of 0.22. Coloplast A/S has a 52-week low of $5.64 and a 52-week high of $10.03. The company has a 50-day simple moving average of $6.10 and a two-hundred day simple moving average of $6.85.

Coloplast A/S (OTCMKTS:CLPBY) last posted its earnings results on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 33.15%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Research analysts anticipate that Coloplast A/S will post 0.38 EPS for the current fiscal year.

Coloplast A/S Company Profile

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.